Clinical Trial Update: Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate for skin changes associated with chronic graft-versus-host disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerotic Graft-versus-host Disease

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sclerotic Graft Versus Host Disease, Imatinib Mesylate | Phase 2 | Status: COMPLETED | Results posted: 2012-11-19